Novocure Ltd (NVCR) - Total Assets
Based on the latest financial reports, Novocure Ltd (NVCR) holds total assets worth $1.36 Billion USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is Novocure Ltd's book value for net asset value and shareholders' equity analysis.
Novocure Ltd - Total Assets Trend (2013–2024)
This chart illustrates how Novocure Ltd's total assets have evolved over time, based on quarterly financial data.
Novocure Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Novocure Ltd's total assets of $1.36 Billion consist of 89.2% current assets and 10.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 13.2% |
| Accounts Receivable | $102.07 Million | 8.2% |
| Inventory | $35.09 Million | 2.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Novocure Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Novocure Ltd market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Novocure Ltd's current assets represent 89.2% of total assets in 2024, a decrease from 97.1% in 2013.
- Cash Position: Cash and equivalents constituted 13.2% of total assets in 2024, down from 93.1% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 8.2% of total assets.
Novocure Ltd Competitors by Total Assets
Key competitors of Novocure Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Demant A/S
CO:DEMANT
|
Denmark | Dkr39.07 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Beijing Wandong Medical Technology Co Ltd
SHG:600055
|
China | CN¥5.70 Billion |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
MODULIGHT OY EO 1
F:78W
|
Germany | €49.14 Million |
|
Diagnostic Medical Systems SA
PA:ALDMS
|
France | €57.17 Million |
|
Theradiag SA
PA:ALTHE
|
France | €11.55 Million |
|
Nova EYE Medical Ltd
AU:EYE
|
Australia | AU$23.67 Million |
Novocure Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.55 | 1.49 | 8.80 |
| Quick Ratio | 1.50 | 1.44 | 8.56 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $423.85 Million | $360.27 Million | $885.83 Million |
Novocure Ltd - Advanced Valuation Insights
This section examines the relationship between Novocure Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.60 |
| Latest Market Cap to Assets Ratio | 1.03 |
| Asset Growth Rate (YoY) | 8.3% |
| Total Assets | $1.24 Billion |
| Market Capitalization | $1.28 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Novocure Ltd's assets above their book value (1.03x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Novocure Ltd's assets grew by 8.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Novocure Ltd (2013–2024)
The table below shows the annual total assets of Novocure Ltd from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.24 Billion | +8.26% |
| 2023-12-31 | $1.15 Billion | -3.82% |
| 2022-12-31 | $1.19 Billion | +4.58% |
| 2021-12-31 | $1.14 Billion | +8.32% |
| 2020-12-31 | $1.05 Billion | +119.42% |
| 2019-12-31 | $479.45 Million | +41.10% |
| 2018-12-31 | $339.79 Million | +28.08% |
| 2017-12-31 | $265.30 Million | -5.95% |
| 2016-12-31 | $282.08 Million | -8.22% |
| 2015-12-31 | $307.34 Million | +160.73% |
| 2014-12-31 | $117.88 Million | -37.60% |
| 2013-12-31 | $188.91 Million | -- |
About Novocure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in br… Read more